Silybin B-d3

• Description:

  Silybin B-d3 (Silibinin B-d3) is a deuterated Silybin B (HY-N7046) . Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394) -induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity[1][2][3][4].

• Product Name Alternative:

  Silibinin B-d3

• UNSPSC:

  12352005

• Target:

  Amyloid-β; Apoptosis; Isotope-Labeled Compounds; JNK; p38 MAPK

• Related Pathways:

  Apoptosis; MAPK/ERK Pathway; Neuronal Signaling; Others

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Cancer; Neurological Disease

• Smiles:

  O=C1[C@H](O)[C@@H](C2=CC=C(O[C@@H](CO)[C@H](C3=CC=C(O)C(OC([2H])([2H])[2H])=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15

• Molecular Formula:

  C25H19D3O10

• Molecular Weight:

  485.45

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-223.|[2]Sciacca MFM, et al. Inhibition of Aβ Amyloid Growth and Toxicity by Silybins: The Crucial Role of Stereochemistry. ACS Chem Neurosci. 2017 Aug 16;8 (8) :1767-1778.|[3]Wang XL, et al. Silybin B exerts protective effect on cisplatin-induced neurotoxicity by alleviating DNA damage and apoptosis. J Ethnopharmacol. 2022 Apr 24;288:114938.|[4]An-Shen Lin, et al. Cancer Preventive Agents. 7. Antitumor-Promoting Effects of Seven Active Flavonolignans from Milk Thistle (Silybum marianum.) on Epstein-Barr Virus Activation, Pharmaceutical Biology, 45:10, 735-738.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported